Immune System News and Research

RSS

Study: Removal of B lymphocytes can reverse aging process

Researchers at the Technion-Israel Institute of Technology have discovered a way to reverse the aging process by removing old B lymphocytes from old mice, and forcing the production of young, potent cells to replace them.

27 Jan 2011

Triggering CD45 molecule blocks early development of AD

A new target for the prevention of adverse immune responses identified as factors in the development of Alzheimer's disease (AD) has been discovered by researchers at the University of South Florida's Department of Psychiatry and the Center of Excellence for Aging and Brain Repair.

27 Jan 2011

Research shows how pathogenic bacteria hide inside host cells

A new study into Staphylococcus aureus, the bacterium which is responsible for severe chronic infections worldwide, reveals how bacteria have developed a strategy of hiding within host cells to escape the immune system as well as many antibacterial treatments. The research, published by EMBO Molecular Medicine, demonstrates how ‘phenotype switching’ enables bacteria to adapt to their environmental conditions, lie dormant inside host cells and become a reservoir for relapsing infections.

26 Jan 2011

Traffic noise and stroke risk: Study

A new study shows that traffic noise may increase the risk of stroke, particularly for older individuals. The study looked at the association between road traffic noise and stroke in more than 51,000 Danish people and found that for every 10-decibel increase in noise level, the risk of stroke increased by 14 percent. In those over 65, the risk of stroke increased 27 percent.

26 Jan 2011

Measles warnings for Australia and New Zealand

In a flight from Brisbane that arrived in Auckland two weeks ago, a child was confirmed to have measles and has been taken to hospital. Five other cases of the virus have been confirmed. At present a further 100 cases are being investigated by the Auckland Regional Public Health Service.

26 Jan 2011

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.

26 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

2011 Japan Prize laureates announced

The Japan Prize Foundation today announced the laureates of its 2011 Japan Prize, one of the world's most prestigious international awards in science and technology.

25 Jan 2011

Regulatory changes needed to protect public health from exposure to toxicants

Americans are exposed to hundreds, if not thousands, of suspected toxic substances every day, substances that affect the development and function of the brain, immune system, reproductive organs or hormones. Children are the most vulnerable. But no public health law requires product testing of most chemical compounds before they enter the marketplace.

25 Jan 2011

Simple means of improving binding affinity of synbodies

Antibodies are watchdogs of human health, continuously prowling the body and registering minute changes associated with infection or disease with astonishing acuity. They also serve as biochemical memory banks, faithfully recording information about pathogens they encounter and efficiently storing this data for later use.

25 Jan 2011

Research finds faster developmental rate incurs lethal physiological costs for individuals

Fast development is often perceived as an advantage, as it enables better harmony with one's environment and readiness to cope with the challenges that it poses. However, research conducted at the University of Haifa, Israel, and University of California, Santa Cruz, and published in the scientific journal PLoS ONE, found that the acceleration of developmental rate incurs potentially lethal physiological costs for the developing individual.

25 Jan 2011

Also in Global Health News: Cholera death in DR; TB vaccine study; Rising food prices

"Dominican Republic on Sunday confirmed that a 53-year-old Haitian man has become the country's first death from cholera and announced the immediate start of a broad disease control and monitoring operation" around the eastern town of Higuey where he was being treated and later died, Latin American Herald Tribune reports (1/24).

24 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Immune Network, a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor, has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis conducted at its second site in Ukraine.

24 Jan 2011

Research findings reveal HIV's hiding spot, new way to stop the virus

HIV adapts in a surprising way to survive and thrive in its hiding spot within the human immune system, scientists have learned. While the finding helps explain why HIV remains such a formidable foe after three decades of research - more than 30 million people worldwide are infected with HIV - it also offers scientists a new, unexpected way to try to stop the virus.

24 Jan 2011

SuppreMol completes successful pre-IND meeting with U.S. FDA

SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound SM101, which is being developed for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE).

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

Odontoblast cells are part of immune system, protect teeth from decay: New research

It is known that teeth can protect themselves, to some extent, from attack by bacteria but that inflammation within a tooth can be damaging and, in extreme cases, lead to abscess or death of the tooth. New research published in BioMed Central's open access journal BMC Immunology shows that odontoblast cells are part of the immune system and fight to protect teeth from decay.

23 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011